secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wave Life Sciences Ltd. (WVE)
CIK:        0001631574
Form:       8-K
Filed at:   2025-12-11T23:59:59+00:00
Accession:  0001193125-25-314746
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wave Life Sciences prices upsized $402.5M public offering; extends cash runway to Q3 2028
--------------------------------------------------------------------------------

- Offering: 15,789,475 shares at $19.00 plus 2,631,578 pre-funded warrants at $18.9999.
- Underwriters fully exercised option for additional 2,763,157 shares; total gross proceeds ~$402.5M.
- Closing expected Dec 11, 2025; pro forma shares outstanding ~187.7M.
- Cash runway extended into Q3 2028; excludes potential milestone payments from GSK collaboration.
- Jefferies, Leerink Partners, BofA Securities act as joint book-running managers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1631574/000119312525314746/0001193125-25-314746-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1631574/000119312525314746/d88507d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-314746

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer